• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Practical aspects of monitoring cardiac drugs in the blood.

作者信息

Wieland H

机构信息

Abteilung Klinische Chemie, Klinikum Universität Freiburg, Federal Republic of Germany.

出版信息

Wien Klin Wochenschr Suppl. 1992;191:48-51.

PMID:1509754
Abstract

Various factors known to affect digoxin blood values are discussed in the present review. A reduction as well as an increase in digoxin levels may be due to the method employed, to errors in the preanalytical phase, to peculiarities of the patient, to diseases or to the administration of drugs. Increased digoxin concentrations above the therapeutic range are much more common than manifestations of digoxin intoxication. However, geriatric patients are specially sensitive to intoxication. Attention has to be paid to digoxin-like immunoreactive factors (DLIF) being synthesized under certain physiologic and pathophysiologic conditions which cause falsely elevated values in digoxin-immunoassays. The determination of digoxin levels is indicated in suspected intoxication or hypersensitivity to digoxin, in patients with pacemakers or those receiving certain drugs, in old people and in patients suffering from any concomitant disease. The time of blood collection has to be carefully controlled in order to determine digoxin concentrations of diagnostic value, the physical activity of the patient being a main influencing factor.

摘要

相似文献

1
Practical aspects of monitoring cardiac drugs in the blood.
Wien Klin Wochenschr Suppl. 1992;191:48-51.
2
Improving the specificity of digoxin immunoassays.提高地高辛免疫测定的特异性。
Wien Klin Wochenschr Suppl. 1992;191:55-9.
3
Endogenous digoxin-like immunoreactive factors (DLIF) as measured by the CEDIA digoxin assay and a fluorescence polarization immunoassay.
Wien Klin Wochenschr Suppl. 1992;191:59-66.
4
Digoxin-like and digitoxin-like immunoreactive substances in elderly people. Impact on therapeutic drug monitoring of digoxin and digitoxin concentrations.
Am J Clin Pathol. 2001 Apr;115(4):600-4. doi: 10.1309/AMD4-X6QR-X5VR-5EM1.
5
Discordant results from "real-world" patient samples assayed for digoxin.
Ann Pharmacother. 2008 Dec;42(12):1797-803. doi: 10.1345/aph.1L225. Epub 2008 Nov 25.
6
Current status of cardiac glycoside drug interactions.强心苷类药物相互作用的现状
Clin Pharm. 1985 Jul-Aug;4(4):404-13.
7
Results of the multicenter evaluation of a homogeneous immunoassay for digitoxin based on the cloned enzyme donor immunoassay technology.基于克隆酶供体免疫分析技术的洋地黄毒苷同质免疫分析多中心评估结果。
Wien Klin Wochenschr Suppl. 1992;191:73-6.
8
CEDIA--homogeneous immunoassays for the 1990s and beyond.CEDIA——面向20世纪90年代及以后的均相免疫分析。
Wien Klin Wochenschr Suppl. 1992;191:5-11.
9
[Drug safety associated with the change of digitalis drug in Norway].[挪威洋地黄类药物变更相关的药物安全性]
Tidsskr Nor Laegeforen. 2016 Nov 8;136(20):1714-1718. doi: 10.4045/tidsskr.15.0161. eCollection 2016 Nov.
10
Receptor kinetics and concentration-effect relation of cardiac glycosides.
Wien Klin Wochenschr Suppl. 1992;191:52-5.